Cargando…

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fürstenau, Moritz, De Silva, Nisha, Eichhorst, Barbara, Hallek, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919470/ https://www.ncbi.nlm.nih.gov/pubmed/31942542 http://dx.doi.org/10.1097/HS9.0000000000000287

Ejemplares similares

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
por: Fürstenau, Moritz, et al.
Publicado: (2021)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Invasive Aspergillosis in Patients Treated With Ibrutinib
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL
por: Kadkol, Shrihari S., et al.
Publicado: (2021)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

72/m mit Zufallsbefund einer Lymphozytose: Vorbereitung auf die Facharztprüfung: Fall 34
por: Langerbeins, Petra, et al.
Publicado: (2022)

COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia
por: Langerbeins, Petra, et al.
Publicado: (2020)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
por: Rawstron, A C, et al.
Publicado: (2016)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Assessment of Minimal Residual Disease in Ewing Sarcoma
por: Wagner, Lars M., et al.
Publicado: (2012)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Honoré, Natasha, et al.
Publicado: (2021)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Shear Wave Elastography in Bruxism—Not Yet Ready for Clinical Routine
por: Toker, Cem, et al.
Publicado: (2023)

Automated LC-MS/MS: Ready for the clinical routine Laboratory?
por: Junger, Sina, et al.
Publicado: (2023)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data
por: Parviz, Mehdi, et al.
Publicado: (2022)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Molecular monitoring of lung allograft health: is it ready for routine clinical use?
por: Pradère, Pauline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a5lohd92tma0emlvi72124s7ro